Avaliação econômica das anticitocinas adalimumabe, etanercepte e infliximabe no tratamento da artrite reumatoide no Estado do Paraná

Venson, Rafael; Wiens, Astrid; Correr, Cassyano Januário; Otuki, Michel Fleith; Grochocki, Mônica Cavichiolo; Pontarolli, Deise Regina Sprada; Pontarolo, Roberto

doi:10.1590/s0103-73312011000200002

Cited by 8 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Em estudo realizado por Venson et al 40 20 . Segundo Lundkvist et al 41 , o custo médio anual por paciente varia conforme o protocolo adotado em cada país, bem como de acordo com a metodologia adotada por cada estudo para estimá-lo.…”

Section: Discussionunclassified

Perfil de gastos com o tratamento da Artrite Reumatoide para pacientes do Sistema Único de Saúde em Minas Gerais, Brasil, de 2008 a 2013

Silva

Andrade

Cherchiglia

et al. 2018

Ciênc. saúde coletiva

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic condition that affects about 1% of the adult population. In a historical cohort of Minas Gerais State, 11,573 RA patients registered in the Outpatient Information System (SIA) between 2008 and 2013 were identified. For this study we adopted the public funding body's perspective and the values were adjusted by the national inflation index (IPCA) of December 2015. Etanercept was the most expensive treatment. The mean cohort age was 52 years old and most of the patients were women. Multiple regression analysis indicated a negative association between higher expenditure and age, female sex, and diagnosis at entry in the cohort and positive association between high expenditure and the Human Development Index (HDI) of the municipality and use of tumor necrosis factor agents. This study identified the factors that have an impact on RA drug treatment expenditure. Also, we showed that methods that enable extracting demographic and expenditure data of administrative information systems may represent important tools in the construction of economic studies to subsidize economic health evaluations, especially from the standpoint of the managers.

show abstract

Section: Discussionunclassified

Perfil de gastos com o tratamento da Artrite Reumatoide para pacientes do Sistema Único de Saúde em Minas Gerais, Brasil, de 2008 a 2013

Silva

Andrade

Cherchiglia

et al. 2018

Ciênc. saúde coletiva

View full text Add to dashboard Cite

show abstract

“…No entanto, um estudo realizado no Paraná sob a perspectiva do SUS, relatou maior efetividade em anos de vida ajustados por qualidade para o etanercepte, seguido de adalimumabe e infliximabe. Além disso, ao considerar os custos dos medicamentos, melhor relação de custo-efetividade foi obtida para o adalimumabe e etanercepte comparados ao infliximabe 16 . Atualmente, também estão aprovados para fornecimento dos MMCD biológicos certolizumabe, golimumabe, rituximabe, abatacepte e tocilizumabe 32 .…”

Section: Discussionunclassified

“…Estudos demonstraram que MMCD biológicos têm custo elevado, sendo o custo anual do tratamento por paciente estimado entre € 13.500 e € 15.000 13 , e cerca de AUD 20.000 14 . No Brasil, Monteiro & Zanini 15 concluíram que um ciclo de tratamento de 48 meses com esquema terapêutico convencional seguido de biológico custou R$ 1.701.286,76, e Venson et al 16 estimaram em R$ 19.698,00 o custo de seis meses de tratamento com infliximabe.…”

Section: Introductionunclassified

Tratamento da artrite reumatoide no Sistema Unico de Saude, Brasil: gastos com infliximabe em comparacao com medicamentos modificadores do curso da doenca sinteticos, 2003 a 2006

et al. 2014

View full text Add to dashboard Cite

This study aimed to characterize the profile of users and related expenses with infliximab and synthetic disease-modifying anti-rheumatic drugs (DMARD) for rheumatoid arthritis treatment in the Brazilian Unified National Health System (SUS). We constructed a cohort from 2003 to 2006 drawing on databases of the SUS Outpatient Information System. Analyses were stratified by clinical and socio-demographic characteristics. We calculated average monthly expenditure per individual follow-up year and the factors that influenced it. The cohort consisted of 26,228 patients, mostly female, between 40 and 59 years of age, living in the Southeast of Brazil, and diagnosed with Felty's syndrome. Medicines for rheumatoid arthritis totalized BRL 74,306,087.18, of which infliximab accounted for 70%. Median monthly per capita expenditure was BRL 3,466.03 for patients receiving infliximab compared to BRL 143.85 for patients treated with synthetic DMARD. Drug treatment for rheumatoid arthritis was the main expense in SUS, with high economic impact from infliximab. Sex, diagnosis, age, and region of residence were factors that influenced expenditures.

show abstract

“…However, to support the physician's choice between anticytokines, that information is not enough, because pharmacoeconomic studies in Brazil are scarce. An economic study has been recently conducted by Venson et al 28 to assess the cost-effectiveness ratio of anticytokines for the RA treatment from the SUS perspective. Among the anticytokines, ADA and ETA showed the best cost-effectiveness ratio (R$511,633.00 and R$437,486.00, respectively) as compared with IFX (R$657,593.00).…”

Section: Discussionmentioning

confidence: 99%

Perfil dos usuários de anticitocinas disponibilizadas pelo Sistema Único de Saúde no estado do Paraná para o tratamento da artrite reumatoide

Wiens¹,

Grochocki²,

Pontarolli³

et al. 2012

Rev. Bras. Reumatol.

Self Cite

View full text Add to dashboard Cite

Introduction: The Brazilian Unifi ed Health Care System (SUS) offers treatment for patients with RA through federal funding (Ministry of Health) and state co-fi nancing. The Clinical Protocol and Therapeutic Guidelines for the treatment of rheumatoid arthritis describe the therapeutic regimen for the disease, including the anticytokines adalimumab, etanercept or infl iximab. Objectives: The aim of this study was to evaluate the profi le of registered users of those anticytokines, biologics registered in the Information System of the Pharmaceutical Assistance Specialized Division, managed by the Paraná State Drug Center. Methods: A cross-sectional study regarding data from March 2010 was conducted. Based on dispensation data, information regarding the following variables were collected: age; gender; regional health care centers; International Classifi cation of Diseases (ICD); and drug dispensed. In addition, the monthly cost with anticytokines for the SUS was calculated. Results: In the state of Paraná, 923 patients on anticytokines were identifi ed, 40%, 44% and 16% of whom receiving adalimumab, etanercept and infl iximab, respectively. This generated a monthly cost of R$3,403,195.59. Regarding the ICD, the distribution of patients was as follows: 55% had ICD M05.8; 27%, ICD M06.0; 9%, ICD M6.8; 8%, ICD M5.0; and 1% had other ICDs related to the disease. The regional health care centers of the state of Paraná with the largest number of patients on anticytokines were in the following municipalities: Ponta Grossa; Cornélio Procópio; Londrina; Cianorte; Maringá; Irati; and Campo Mourão. Conclusion: This study assessed the distribution and profi le of users of anticytokines for the rheumatoid arthritis treatment covered by the SUS in the state of Paraná, in March 2010.

show abstract

Avaliação econômica das anticitocinas adalimumabe, etanercepte e infliximabe no tratamento da artrite reumatoide no Estado do Paraná

Cited by 8 publications

References 19 publications

Perfil de gastos com o tratamento da Artrite Reumatoide para pacientes do Sistema Único de Saúde em Minas Gerais, Brasil, de 2008 a 2013

Perfil de gastos com o tratamento da Artrite Reumatoide para pacientes do Sistema Único de Saúde em Minas Gerais, Brasil, de 2008 a 2013

Tratamento da artrite reumatoide no Sistema Unico de Saude, Brasil: gastos com infliximabe em comparacao com medicamentos modificadores do curso da doenca sinteticos, 2003 a 2006

Perfil dos usuários de anticitocinas disponibilizadas pelo Sistema Único de Saúde no estado do Paraná para o tratamento da artrite reumatoide

Contact Info

Product

Resources

About